MSD’s investigational KRAS G12C inhibitor has shown signs of anti-tumour activity when used both alone and with other ...

Diakonos Oncology has closed a $20m private placement of Simple Agreements for Future Equity (SAFE) for its Phase II trial of ...

Sanofi and Regeneron have reported that the Phase III AERIFY-1 trial of the fully human monoclonal antibody itepekimab.

Phase III progression-free survival data were positive for first-line Braftovi in first-line combination therapy for mCRC.

Biohaven has started a randomised Phase II/III trial of the TYK2 / JAK1 inhibitor, BHV-8000, aimed at treating early ...

Zilovertamab vedotin, an antibody drug conjugate (ADC) developed by Merck & Co (MSD) to treat diffuse large B-cell lymphoma ...

Auron has dosed the first subject in the Phase I trial of AUTX-703, targeting individuals with advanced haematologic ...

After Lykos' rejection from the FDA last year, companies trying to navigate the psychedelic drug trial sector face various ...

Alumis has concluded enrolment in its pivotal Phase III ONWARD programme of ESK-001 for treating plaque psoriasis.

Intellia's news comes at a challenging time for gene therapies, as multiple serious adverse events and fatalities have been ...

Experts discuss the use of artificial intelligence (AI) and patient-centric strategies in oncology clinical trials.

GSK plans to submit to the US Food and Drug Administration (FDA) for regulatory approval of tebipenem HBr by the end of 2025.